<SEC-DOCUMENT>0001043961-19-000017.txt : 20190926
<SEC-HEADER>0001043961-19-000017.hdr.sgml : 20190926
<ACCEPTANCE-DATETIME>20190926164346
ACCESSION NUMBER:		0001043961-19-000017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190926
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20190926
DATE AS OF CHANGE:		20190926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		191118374

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prpo-20190926x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 9/26/2019 4:42:08 PM-->
<html>
	<head>
		<title>
			PRPO-8K - Regulation FD Discklosure Press Release dated Sep 26, 2019
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<div style="margin-bottom:8pt;"><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 14pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:14pt;">UNITED STATES&nbsp;SECURITIES AND EXCHANGE COMMISSION<br /></font><font style="display:inline;font-family:Calibri Light;font-size:10pt;"></font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;">WASHINGTON, D. C. 20549</font>
		</p>
		<div style="margin-bottom:8pt;"><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 16pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:16pt;">FORM 8-K </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;">CURRENT REPORT<br />PURSUANT TO SECTION 13 OR 15(d) OF THE<br />SECURITIES EXCHANGE ACT OF 1934 </font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Date of report (Date of earliest event reported): September 26, 2019 </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 16pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:16pt;">PRECIPIO, INC.<br /></font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(Exact Name of Registrant as Specified in Its Charter)</font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:29.04%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.66%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:29.86%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.66%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.78%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.04%;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;">Delaware<br /></font><font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(State of Incorporation)</font></p>
				</td>
				<td valign="top" style="width:02.66%;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:29.86%;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-weight:bold;color:#000000;font-size:10pt;">001-36439<br /></font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(Commission File Number)</font></p>
				</td>
				<td valign="top" style="width:02.66%;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.78%;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-weight:bold;color:#000000;font-size:10pt;">91-1789357<br /></font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(I.R.S. Employer Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;color:#000000;font-size:10pt;">4 Science Park, New Haven, CT 06511</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(Address of principal executive offices) (Zip Code)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;">(203) 787-7888</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(Registrant's telephone number, including area code)</font>
		</p>
		<a name="page_de1292_1_2"></a><div style="margin-bottom:8pt;"><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;color:#000000;font-size:10pt;">Not Applicable<br /></font><font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Calibri Light;font-style:italic;font-size:10pt;">(Former name, former address and former fiscal year, if changed since last report date)</font>
		</p>
		<div style="margin-bottom:8pt;"><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 2pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font>
		</p>
		<p style="margin:0pt 0pt 2pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Calibri Light;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Calibri Light;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font>
		</p>
		<p style="margin:0pt 0pt 2pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Calibri Light;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Calibri Light;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font>
		</p>
		<p style="margin:0pt 0pt 2pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Calibri Light;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Calibri Light;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font>
		</p>
		<p style="margin:0pt 0pt 2pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Calibri Light;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Calibri Light;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:1.00pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:1.00pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:1.00pt">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:560.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Ticker symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:16.50pt">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Common Stock, $0.01 par value per share</font></p>
				</td>
				<td valign="bottom" style="width:190.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:16.50pt">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">PRPO</font></p>
				</td>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:16.50pt">
					<p style="margin:0pt 0pt 4pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">The Nasdaq Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 2pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font>
		</p>
		<p style="margin:0pt 0pt 2pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Emerging growth company </font><font style="display:inline;font-size:10pt;">&#x2610;</font>
		</p>
		If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<div style="margin-bottom:2pt;"><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></hr></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-weight:bold;color:#000000;font-size:10pt;">Item 7.01 <font style="display:inline;font-family:inherit;font-weight:bold;color:#000000;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Regulation FD Disclosure</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">On September 26, 2019, Precipio, Inc (the "</font><font style="display:inline;font-family:inherit;font-weight:bold;color:#000000;font-size:10pt;">Company</font><font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">") issued a press release with update regarding the Company&#x2019;s clinical validation status being completed.&nbsp;&nbsp;A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#x201C;filed&#x201D; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-weight:bold;color:#000000;font-size:10pt;">Item 9.01 Financial Statements and Exhibits</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">(d) Exhibits</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:normal;color:#000000;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">99.1<font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;<a href="prpo-20190926ex99100f5cc.htm"></font><font style="display:inline;font-family:inherit;font-size:10pt;">Press Release dated September 26, 2019</a></font><font style="display:inline;font-family:inherit;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;">SIGNATURE </font>
		</p>
		<p style="margin:12pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 99.32%;margin-left:3.25pt;">
			<tr>
				<td valign="top" style="width:45.04%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:54.96%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-weight:bold;font-size:10pt;">PRECIPIO, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.04%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:54.96%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.04%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.40%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="width:45.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">/s/ Ilan Danieli</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.04%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.40%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:45.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Ilan Danieli</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.04%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.40%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:45.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:normal;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri Light;font-size:10pt;">Date:<font style="display:inline;font-family:Calibri Light;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>September 26, 2019&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prpo-20190926ex99100f5cc.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 9/26/2019 4:42:12 PM-->
<html>
	<head>
		<title>
			PRPO - 8K - 99.1Press release Dated Sep 26, 2019
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"><img src="prpo20190926ex99100f5cc001.jpg" style="width: 3.822917in; height: 0.75in" alt="Og1WnbOapgrBYoYFqg4oV2ZrN1yQsQLOWZCU-4W2gWe-D6hf580TPlHFoZ5lMmZuQ49htFtmqL5UnjsjeC5tFWy1IGFjnY0hKRFLQm-hT8De_4l1jdc9SsG0WjKGhlP42uuMSi5esrr-6gOvYg"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;color:#000000;font-family:Calibri;font-size: 14pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:14pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 14pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:14pt;">Clinical Validations for IV-Cell&#x2122; and HemeScreen&#x2122; Completed</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;color:#000000;font-size:12pt;">&nbsp;Orders expected from several major labs both domestically and internationally</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">NEW HAVEN, CT, (September 27, 2019) &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Specialty diagnostics company </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;">Precipio, Inc.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;"> &nbsp;(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">NASDAQ: &nbsp;PRPO</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">), announced that as it approaches the end of Q3-2019, several of the large laboratories have successfully completed validation studies to test Precipio&#x2019;s&nbsp; IV-Cell cytogenetics media product, as well as its HemeScreen Assay, and are proceeding towards placing orders.</font><font style="display:inline;font-family:Calibri;color:#000000;">&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">From Validation Testing To Revenue</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As previously discussed, each lab must undergo a complex and thorough process to introduce products such as IV-Cell cytogenetics media and HemeScreen Assay into its clinical work-flow. This includes extensive testing as well as side-by-side comparison to the laboratory&#x2019;s existing process in order to ensure both consistent results, as well as superior performance of the products.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Each potential customer has their unique acceptance procedures.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Only once these and other important parameters are demonstrated, does a laboratory proceed to discuss purchasing this product and integrating it into their clinical operations.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">&#x201C;This process is no different than the process we at Precipio take when evaluating and introducing a new technology; after all, we are dealing with patients&#x2019; lives and the diagnosis of cancer, a task we take incredibly seriously. Therefore a rigorous process is expected to ensure accuracy of results&#x201D; said Dr. Ayman Mohamed, Precipio&#x2019;s Laboratory Scientific Director.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">In the laboratories that have completed their clinical testing step, the next and final step is the agreement on commercial terms. Based on the size of the customer, this usually involves various approvals within the organizational hierarchy; followed by a pricing/volume discussion to establish the economic terms. Finally, the laboratory must evaluate its current inventory levels to assess the timeline to exhausting the inventory it has on hand of its current products (typically 30-60 days&#x2019; worth of inventory) and place an order accordingly.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">New Product Commercialization Efforts</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Precipio management and its commercial team have been engaged in substantial efforts to commercialize its products, including in-roads into some of the largest laboratories both domestically and internationally.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As with many new products, the first sale is always the most difficult one. Absent a product track record and prior customer references, the product introduction is challenging. However, the combination of the clinical value of products such as IV-Cell, combined with its operational and cost-advantage benefits, have proven extremely attractive to the customers approached by Precipio.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Over the past six months the team has been focused on approaching customers and obtaining agreements for trials. As in all sales, this is very much a &#x201C;shots on goal&#x201D; approach, and the more </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">customers the company approaches, the more trials are conducted, the more end-user customers we project to have.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">The company has had substantial success (as measured by the response rates) and has a pipeline of numerous additional trials underway both domestically and internationally.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">As typically in new product launches, through frequent meetings and presentations to customers, the company continuously learns how to improve its product positioning and marketing message. We have also been able to identify the key benefits that are important to customers. That feeds into an improved message which ultimately increases the yield of sales efforts.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">The company's commercialization efforts internationally have enabled for&nbsp;trials that were successfully secured for IV-Cell, with revenue potential estimated at $5M annually. The seven trials were generated from a total of eight laboratories that were presented with the product.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">&#x201C;We are energized by the results of the commercialization of our products. I have witnessed firsthand our recent successes in generating interest, trials, and successful results for labs both in the US and overseas; this clearly demonstrates we have a product that combines clinical, operational and economic value to laboratories serving their patients&#x201D;, said Ilan Danieli, Precipio&#x2019;s Chief Executive Officer. &#x201C;I have no doubt that proprietary technologies such as IV-Cell will be a substantial driver of revenue, gross margin, and profitability in the coming quarters - yes it takes longer time than anticipated but I am confident that we are on the right path forward to creating substantial shareholder value.&#x201D;&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">About Precipio</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard&#x2019;s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">www.precipiodx.com</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">.&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Certain statements in this press release constitute &#x201C;forward-looking statements,&#x201D; within the meaning of federal securities laws, including statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and prospects and other statements containing the words &#x201C;anticipate,&#x201D; &#x201C;intend,&#x201D; &#x201C;may,&#x201D; &#x201C;plan,&#x201D; &#x201C;predict,&#x201D; &#x201C;will,&#x201D; &#x201C;would,&#x201D; &#x201C;could,&#x201D; &#x201C;should,&#x201D; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company&#x2019;s definitive proxy statement filed on April 19, 2019 , the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and on the Annual Report on Form 10-K for the year ended December 31, 2018 as well as the Company&#x2019;s prior filings and from time to time in the Company&#x2019;s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">Inquiries:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#1155CC;font-size:10pt;text-decoration:underline;">investors</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#1155CC;font-size:10pt;">@precipiodx.com</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:10pt;">+1-203-787-7888</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>prpo20190926ex99100f5cc001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 prpo20190926ex99100f5cc001.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D TH# 2(  A$! Q$!_\0
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M^%('_H/#_P !?_LZ/^%('_H/#_P%_P#LZTY:/<5Y'4_\+6\(_P#/]-_X#O\
MX4?\+6\(_P#/]-_X#O\ X5RW_"D#_P!!X?\ @+_]G1_PI _]!X?^ O\ ]G1R
MT>X7D=3_ ,+5\)?\_P!+_P" [_X5/;?$OPE=.$&JK&QZ>;$ZC\R,5Q__  I
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M7_/]+_X#O_A4/C'X<0>*]3CU!=0:TF$8C<&/>K 9P>HP>:YS_A1Y_P"@\/\
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M-:7BD@#TP>5_"E[%2^!AS/J?2%+UKB_"7Q#TSQ-MMW/V34,<P2-P_P#N'O\
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M (FMW_A47A?_ )YW?_?\T?\ "HO"_P#SSN_^_P":+T>PO>,+_A=\'_0"D_\
M D?_ !-12_&Y=A$.A'?V+W7 _P#':Z+_ (5%X7_YYW?_ '_-.C^$WA1&RUM<
M2#T:=L'\L47H]A^\>4Z_X[\0^*V^R,YC@D.!:VJGY_0'NWTKL? ?PQECGBU;
MQ!$%V$-#9MR<]B_^'Y^E>CZ5X:T;0P?[-TV"!L8WJN7/_ CS^M:]*5;3E@K
MH]6+1116)1A^)O$=MX7T9]1ND>10P1(TZNQ[>W0UP7_"[X/^@%)_X$C_ .)K
M7^,8SX,C/I=I_P"@M7$_#7P?I/BBVU&34EF8P.@3RY-O4'/\JWIPAR<TB&W>
MR-__ (7?!_T I/\ P)'_ ,31_P +O@_Z 4G_ ($C_P")K=_X5%X7_P">=W_W
M_-'_  J+PO\ \\[O_O\ FB]'L'O&%_PN^#_H!2?^!(_^)I/^%X0?] *3_P "
M1_\ $UO?\*B\+_\ /.[_ ._YH_X5%X7_ .>=W_W_ #1>CV#WC!_X7?#_ - .
M3_P)'_Q-5;SXV7#1%;'18XWQP\TY<#\ !_.NH_X5%X7_ .>=W_W_ #4MI\+O
M"4;"06;SX_OW#$9_ T^:CV#WCQVZOO$GCO54C8SWLV?DBC&(XQ].B_4U[!X$
M\!0^%H?M=T4FU25<,X'RQ#^ZO]376V.FV.FP>38VD-M%_=B0*#^56ZB=;F5E
MHAJ(M%%%9%'A7QG_ .1ML_\ KR7_ -#>O5/ W_(CZ-_UZI7E?QG_ .1MM/\
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MPM\)Q3))_9[OM.=KSN0?J,T<U'L%I'7P3)<V\4\9S'(H=2?0C(J:F*H50J@
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ML7/_  )C_P#$US=IX/N+FS@N%4[98U<<>HS7H4;<BN92W/I*BBBO/-0HHHH
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MXQVYF\'0S ?ZF[1C]"K#^HKPBN[#I.!E/<TE\0ZVGW=8U!?I<O\ XU*OBGQ
MO36]1_\  I_\:R**VY43=FXOC'Q*G37=0_&X:O3?A'K^I:Q-JT6I7T]T8UB:
M/S7W;?O9Q^E>+5Z!\(=1%IXP-JQPMW R#_>'S#] :RJP7([(J+U/?****X#4
M**** "BBB@ HHHH **** ,+Q@P3PCJA/_/NP_/BO *]K^)-X+7PC-%D!KB1(
MA^>X_P#H->*5Z6#7N-G/5W"BBBNLR.S^&*D^+@1T%NY/Z?XU[37D/PI@+Z]>
M3XXCM]OXEA_@:]>KR<4_WATTOA"BBBL#0HZQ_P @6_\ ^O:3_P!!->"?"O\
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M&+D[(5['4ZYKECX>TV2^U"4)$H^5?XG;LJCN:^?M4U'5O'_BM-D9:69O+MX
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M*_\ GO;?]^!2?\+:\5_\_%M_WX%>X_\ "/Z+_P! ?3__  &3_"C_ (1_1?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEWDU[\-)Y+AS)*+2>,N?X@NY0?R K:\,C_BEM*_Z](O_ $$4[))W%>^QG_\
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M -"KIN]<UX'_ .01=?\ 7]/_ .A5TO>G+XF*.PM%%%(9S'C_ /Y$O4/^ ?\
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0 A+,V23M')HHKFCL:,__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
